Panacea
发表于 2025-3-26 22:21:11
Chemotherapy for Advanced Non-small Cell Lung Cancer,cular drivers and the role of the immune system in cancer therapy have brought new drugs to the armamentarium. Despite these advances, cytotoxic chemotherapy remains a substantial part of therapy for most patients in locally advanced and metastatic stage. Initially thought to be a chemotherapy-resis
DIS
发表于 2025-3-27 03:19:28
Multimodality Therapy for NSCLC, Although the concurrent use of both treatment modalities has been shown to be superior to sequential therapy, the role for additional chemotherapy, either as induction or as consolidation, remains unclear. Targeted therapy has met limited success in the treatment of unselected patients with stage I
放肆的你
发表于 2025-3-27 07:36:17
http://reply.papertrans.cn/59/5891/589061/589061_33.png
Parley
发表于 2025-3-27 10:03:27
Immunotherapy in Lung Cancer,vital to malignant progression. Immunotherapies act by enhancing the patient’s innate immune response and hold promise for inducing long-term responses in select patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immune checkpoint inhibitors, in particular, inhibitor
功多汁水
发表于 2025-3-27 16:01:39
Palliative Care in Lung Cancer, with advanced lung cancer is very high and has a negative impact on their quality of life (QOL). Palliative care with its focus on the management of symptoms and addressing physical, psychosocial, spiritual, and existential suffering, as well as medically appropriate goal setting and open communica
托运
发表于 2025-3-27 20:41:48
Management of Lung Cancer in the Elderly,e-half of patients with lung cancer fall into the elderly subgroup. There is dearth of high level of evidence regarding the management of lung cancer in the elderly in the three broad stages of the disease including early-stage, locally advanced, and metastatic disease. A major reason for the lack o
enlist
发表于 2025-3-28 01:22:15
http://reply.papertrans.cn/59/5891/589061/589061_37.png
Cleave
发表于 2025-3-28 03:44:44
Small Cell Lung Cancer,y present with a short duration of symptoms and frequently (60–65 %) with metastatic disease. SCLC is a heterogeneous disease including extremely chemosensitive and chemoresistant clones. For this reason, a high percentage of patients respond to first-line chemotherapy but rapidly succumb to the dis
corpus-callosum
发表于 2025-3-28 08:33:31
http://reply.papertrans.cn/59/5891/589061/589061_39.png
地牢
发表于 2025-3-28 11:12:19
http://reply.papertrans.cn/59/5891/589061/589061_40.png